Evidence map›Paper›PMID 41079525›Full record

ArticleThe mental health clinician2025

Dual long-acting injectable antipsychotic use in treatment-resistant schizophrenia with extensive hospitalization history: A case report.

Lily Zheng, Archana Jhawar

Abstract readCase Reports
In one paragraph

Article in The mental health clinician, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lily Zheng(Corresponding author) Resident Physician, Department of Psychiatry, University of Illinois Chicago, Chicago, Illinois, zhenglily0@gmail.com.ORCID https://orcid.org/0009-0005-2539-4514
Archana JhawarClinical Assistant Professor, Retzky College of Pharmacy, University of Illinois Chicago, Chicago, Illinois; Clinical Pharmacy Practitioner, Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois.ORCID https://orcid.org/0000-0003-2317-5586

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment-resistant schizophrenia (TRS) is a challenging condition to manage and can result in the need for dual antipsychotic prescribing especially after oral clozapine failure. Poor medication adherence is prevalent among patients with TRS, and long-acting injectable antipsychotics are frequently used to overcome this barrier. Whereas there is limited data on the risks and benefits of dual long-acting injectable antipsychotic treatment, this is a treatment modality that is being used for patients with TRS who have poor adherence. We contribute a case of successful dual long-acting injectable therapy with intramuscular paliperidone palmitate and haloperidol decanoate in a patient with TRS and an extensive history of hospitalizations who failed treatment with oral clozapine.

Indexed as

dual long-acting antipsychoticschizoaffective disordertreatment-resistant schizophrenia

Identifiers

PMID41079525
PMCPMC12510625

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.